BridgeBio Pharma, Inc. (BX:BBIO) Financings

BridgeBio Pharma, Inc.

Financings

RaiseDate
Preferred equity
Closed: US$1B raised
Buyers: Sixth Street (led the financing); HealthCare Royalty
Use of proceeds: Fund three potential upcoming launches while continuing to invest in indication expansion across the pipeline
Aug 10, 2026
Series A Cumulative Convertible Participating Preferred Stock
Closed: convertible
Buyers: Sixth Street (funded $800M as the lead investor); HealthCare Royalty (funded $133.9M)
Use of proceeds: Strengthen the balance sheet and allocate capital across its highest return opportunities, including product launches
Jul 1, 2026
0.75% convertible senior notes due 2033
Update: US$550M
Use of proceeds: Repurchase, settle conversions of or repay part of the 2.50% convertible notes due 2027, and general corporate purposes
Jan 15, 2026
1.75% convertible senior notes due 2031
Update: US$500M
Use of proceeds: Repay and terminate the Blue Owl Financing Agreement, repurchase about $48.3 million of common stock, and general corporate purposes
Feb 25, 2025

Read by 6ix AI from the company's releases